Compare MEI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | VNDA |
|---|---|---|
| Founded | 1946 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 474.0M |
| IPO Year | 1994 | 2005 |
| Metric | MEI | VNDA |
|---|---|---|
| Price | $8.46 | $8.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $14.13 |
| AVG Volume (30 Days) | 345.5K | ★ 3.5M |
| Earning Date | 03-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 49.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $908,300,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $26.20 |
| Revenue Next Year | $3.66 | $31.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | 8.72 |
| 52 Week Low | $5.08 | $3.81 |
| 52 Week High | $10.24 | $9.60 |
| Indicator | MEI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 57.63 |
| Support Level | $8.42 | $4.25 |
| Resistance Level | $8.61 | $8.29 |
| Average True Range (ATR) | 0.42 | 0.54 |
| MACD | -0.09 | 0.21 |
| Stochastic Oscillator | 26.72 | 74.26 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.